HOME > LATEST

LATEST

BUSINESS JCR Expects Strong Returns from Recently In-Licensed DMD Drug: CEO

January 26, 2026
BUSINESS Solasia to Grant MAAB Rights to Antiemetic Drug in China

January 26, 2026
BUSINESS Toho Seeks Additional Disclosure from 3D over Proposed Share Purchases

January 26, 2026
REGULATORY Chuikyo OKs Health Coverage for Optune Lua, CDx for Inluriyo and Elevidys

January 26, 2026
REGULATORY Japan to Bolster Reimbursement Incentives for Biosimilars in FY2026 Fee Revision

January 26, 2026
REGULATORY Japan Panel OKs AbbVie’s Aquipta, Ipsen’s Sohonos, and Novo’s IcoSema for Approval

January 26, 2026
BUSINESS J&J Seeks Pediatric UC Indication for Stelara in Japan

January 26, 2026
BUSINESS Will Unlisted AGs Rush for June Listing or Be Left on Ice?

January 23, 2026
REGULATORY Japan’s 1st Xolair Biosimilar Likely from Celltrion as JAN Is Assigned

January 23, 2026
REGULATORY DPP Vows to Scrap Off-Year Drug Price Revisions in Election Platform

January 23, 2026
REGULATORY Japan Starts Review on Scope of Drugs Eligible for Immunization Use, with Beyfortus in Focus

January 23, 2026
ORGANIZATION Off-Year Drug Price Revisions Run Counter to Innovation, JPMA Exec Says

January 23, 2026
BUSINESS Enhertu Reels in 6th China Indication in Second-Line Gastric Cancer

January 23, 2026
BUSINESS Maruho Out-Licenses Rapifort to Taiwan’s Orient EuroPharma

January 23, 2026
REGULATORY Takeda’s Miyabashira Urges National Strategy Act to Revive Japan as Innovation Powerhouse

January 22, 2026
REGULATORY LDP Pledges to Position Pharma as Core Industry in Campaign Platform

January 22, 2026
BUSINESS Towa to Take Over Manufacturing of Otsuka’s LLPs in Cross-Sector Tie-Up

January 22, 2026
REGULATORY Many Pharma-Savvy Lawmakers on LDP’s Candidate Roster for Lower House Poll

January 22, 2026
REGULATORY Japan Health Minister Says Early Call on FY2027 Off-Year Revision Improves Predictability

January 22, 2026
REGULATORY Japan Grants Sakigake Tag to Nanoscope’s MOGENRY

January 22, 2026

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…